Physician profile
David Rotman
NPI 1730204405
$508.84
in general payments reported to CMS, 2019-2025
13 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.33 · 2020: $47.30 · 2021: $16.68 · 2022: $37.19 · 2023: $108 · 2024: $81.19 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $180.59 | 2022-2025 | Jardiance, Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.72 | 2024-2025 | Jardiance, Synjardy |
| Avanir Pharmaceuticals, INC. | $51.13 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $33.85 | 2024-2025 | Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $33.27 | 2023 | Nuedexta, Rexulti |
| Glaxosmithkline, LLC. | $23.17 | 2023 | Bexsero |
| Corium, LLC | $20.33 | 2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.90 | 2023 | Xifaxan |
| Abbvie INC. | $15.49 | 2025 | |
| Novo Nordisk INC | $14.79 | 2025 | |
| Astellas Pharma US INC | $14.42 | 2024 | Veozah |
| Bardy Diagnostics, INC. | $12.85 | 2020 | |
| Mylan Specialty L.P. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rotman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.